Monoclonal antibody · Antagonist of SARS-CoV-2 spike protein · developed by AstraZeneca
Cilgavimab/Tixagevimab is a combination of two neutralizing human monoclonal antibodies, cilgavimab and tixagevimab, that bind the SARS-CoV-2 spike (S) protein and block viral attachment and entry into human cells. It is studied in COVID-19 for passive immunization.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04518410 | Phase 2/3 | Coronavirus | Completed | SABS |
| NCT04501978 | Phase 3 | Covid19 | Completed | VIR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CoronavirusCovid19
Updated Nov 1, 2026.